Cotiviti Gears Up for Secondary Offering
Cotiviti intends to offer 10 million shares in a secondary offering that could be valued up to more than $361 million.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 185
Recro Pharma Rises on Late Stage Win
Recro Pharma shares saw a handy gain on Monday after the company announced positive late-stage results on its acute postoperative pain treatment.
PhaseRx More Than Doubles on Key FDA Approval
Shares of PhaseRx more than doubled on Monday after the company announced that it received a key FDA approval for its rare liver disorder treatment.
Short Sellers Grow More Aggressive on Major Biotechs
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
Short Sellers Hike Their Bets in Most Major Pharma Stocks
The November 15 short interest data have been compared with the previous figures, and short interest was mixed in the selected pharmaceutical stocks.
Juno Falls Sharply on Self-Imposed Clinical Hold
Juno Therapeutics Inc. (NASDAQ: JUNO) saw its shares hit a new 52-week low in Wednesday’s session after the company announced a clinical hold on its JCAR015 trial. The company announced that it has voluntarily…
Why Eli Lilly Won’t Forget This Alzheimer’s Failure Anytime Soon
Eli Lilly & Co. (NYSE: LLY) is watching its shares in free fall on Wednesday, not from any election or political concerns but a late-stage trial failure. As we have said time and again,…
Skyline Medical Doubles on Canada Deal
Skyline Medical Inc. (NASDAQ: SKLN) is watching its shares more than double in Tuesday’s session after the company issued a key update for its prospective Canada sales. The company announced that it has received…
Amedica Slides on Mixed FDA Updates
Amedica Corp. (NASDAQ: AMDA) is watching its shares drop on Tuesday despite receiving mixed news from the U.S. Food and Drug Administration, along with a new appointment to its management team. Although the FDA…
Oragenics Practically Doubles on FDA Decision
Oragenics Inc. (NYSEMKT: OGEN) saw its shares practically double late on Monday, and even continue climbing after the trading session ended, following an update from the U.S. Food and Drug Administration (FDA). The agency…
Positive Analyst Ratings Not Enough to Drive Myovant Sciences Higher
Myovant Sciences Ltd. (NYSE: MYOV) priced its initial public offering of 14.5Â million common shares on October 27, 2016. Now its quiet period has come to an end and the analysts at firms in the…
Acorda Slides on Clinical Study Update
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is watching its shares slide on Monday after the company gave an update on a recent clinical study. Essentially, the company announced that its Milestone clinical study did not…
Aclaris Files for Secondary Offering
Aclaris Therapeutics saw its shares make a handy gain on Friday after the company announced the pricing of its secondary offering.
EyeGate Pharma Rises After FDA Meeting
Eyegate Pharmaceuticals saw its shares make a strong gain to close out the week after the company announced an update from its meeting with the FDA.
Why NovoCure Shares Could Double, or Rise Even More
With the market effectively at all-time highs after the election, investors are looking for new ideas to generate income or gains ahead. Sometimes investors turn to Wall Street research to look for hidden gems…